Method and device for monitoring an analyte concentration in the living body of a human or animal

0Associated
Cases 
0Associated
Defendants 
0Accused
Products 
116Forward
Citations 
0
Petitions 
3
Assignments
First Claim
1. A method for continuous monitoring of an analyte concentration in the living body of a human or animal, the method comprising:
 determining an analyte values y(t_{n}) correlating with the concentration of the analyte for consecutive points in time t_{n};
calculating a prediction value y(t_{n0}+Δt) over a prediction period Δt based on the analyte value y(t_{n}) using the following equation;
y(t_{n0}+Δt)=F(t_{n0}, t_{n0−Δn}, . . . , t_{(n0−(m−2)Δn)}, t_{(n0−(m−1)Δn)}); and
generating a warning signal if the prediction value y(t_{n0}+Δt) deviates from a predetermined value by more than a threshold value, wherein function F(t_{k}, t_{k−Δn}, t_{k−2Δn}, . . . , t_{k−(m−2)Δn}, t_{k−(m−1)Δn}) depends on the analyte values y(t_{k}), y(t_{k−Δn}), y(t_{k−2Δn}), . . . , y(t_{k−(m−2)Δn}), y(t_{k−(m−1)Δn}) and the function F is used to approximate the progression of the analyte values y(t_{n}) at time t_{n0 }in vicinity U of an analyte value y(t_{n0}) with a predetermined accuracy σ, such that $\begin{array}{c}{\sigma}^{2}\ge \sum _{{t}_{k}\in U}[y\left({t}_{k}\right)F({t}_{k}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{k\Delta \phantom{\rule{0.3em}{0.3ex}}n}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{k2\Delta \phantom{\rule{0.3em}{0.3ex}}n}\hspace{1em}\hspace{1em}\\ {\hspace{1em}\hspace{1em}\Delta \phantom{\rule{0.3em}{0.3ex}}t,\dots \phantom{\rule{0.8em}{0.8ex}}{t}_{\left(k\left(m2\right)\Delta \phantom{\rule{0.3em}{0.3ex}}n\right)}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{\left(k\left(m1\right)\Delta \phantom{\rule{0.3em}{0.3ex}}n\right)}\Delta \phantom{\rule{0.3em}{0.3ex}}t)]}^{2}\end{array}$ whereby n_{0}, m, and Δn are integers.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to a method and a device for monitoring an analyte concentration in the living body of a human or animal. In particular to a method and device for determining analyte values y(tn) correlating with the concentration to be determined are determined for consecutive points in time tn. The analyte values y(tn) is used to predict a prediction value for an analyte y(tn0+Δt) over a prediction period Δt.
123 Citations
Method and apparatus for lancet launching device integrated onto a bloodsampling cartridge  
Patent #
US 7,909,775 B2
Filed 06/26/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,914,465 B2
Filed 02/08/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,909,774 B2
Filed 02/13/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for body fluid sampling and analyte sensing  
Patent #
US 7,892,183 B2
Filed 07/03/2003

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for a multiuse body fluid sampling device with sterility barrier release  
Patent #
US 7,875,047 B2
Filed 01/25/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,909,778 B2
Filed 04/20/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,909,777 B2
Filed 09/29/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,901,365 B2
Filed 03/21/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 7,938,787 B2
Filed 09/29/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Universal Models for Predicting Glucose Concentration in Humans  
Patent #
US 20110160555A1
Filed 07/31/2009

Current Assignee
Rajaraman Srinivasan, Gribok Andrei, Gani Adiwinata, Reifman Jacques

Sponsoring Entity
Rajaraman Srinivasan, Gribok Andrei, Gani Adiwinata, Reifman Jacques

Method and apparatus for penetrating tissue  
Patent #
US 7,959,582 B2
Filed 03/21/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus for penetrating tissue  
Patent #
US 8,007,446 B2
Filed 10/19/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a multiuse body fluid sampling device with sterility barrier release  
Patent #
US 7,988,644 B2
Filed 03/21/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods And Systems For Processing Glucose Data Measured From A Person Having Diabetes  
Patent #
US 20110184267A1
Filed 01/26/2010

Current Assignee
Roche Diabetes Care Inc.

Sponsoring Entity
Roche Diabetes Care Inc.

Tissue penetration device  
Patent #
US 8,016,774 B2
Filed 12/22/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 7,981,056 B2
Filed 06/18/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Device and method for variable speed lancet  
Patent #
US 7,976,476 B2
Filed 03/16/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Tissue penetration device  
Patent #
US 7,981,055 B2
Filed 12/22/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
Pelikan Technologies Inc.

Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties  
Patent #
US 7,988,645 B2
Filed 05/03/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,062,231 B2
Filed 10/11/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Medical data transmission system  
Patent #
US 20100141429A1
Filed 09/09/2009

Current Assignee
Roche Diabetes Care Inc.

Sponsoring Entity
Roche Diabetes Care Inc.

ANALYTE MONITORING SYSTEM ALARMS  
Patent #
US 20090160656A1
Filed 10/14/2008

Current Assignee
OptiScan Biomedical Corporation

Sponsoring Entity
OptiScan Biomedical Corporation

Method and apparatus for lancet launching device integrated onto a bloodsampling cartridge  
Patent #
US 8,123,700 B2
Filed 06/26/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 8,079,960 B2
Filed 10/10/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 8,157,748 B2
Filed 01/10/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,162,853 B2
Filed 12/22/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,197,421 B2
Filed 07/16/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,197,423 B2
Filed 12/14/2010

Current Assignee
Pelikan Technologies Inc.

Sponsoring Entity
Pelikan Technologies Inc.

Tissue penetration device  
Patent #
US 8,206,317 B2
Filed 12/22/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,206,319 B2
Filed 08/26/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,211,037 B2
Filed 12/22/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,216,154 B2
Filed 12/23/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,221,334 B2
Filed 12/22/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,235,915 B2
Filed 12/18/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for body fluid sampling and analyte sensing  
Patent #
US 8,251,921 B2
Filed 06/10/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for fluid injection  
Patent #
US 8,262,614 B2
Filed 06/01/2004

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for body fluid sampling with hybrid actuation  
Patent #
US 8,267,870 B2
Filed 05/30/2003

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for an improved sample capture device  
Patent #
US 8,282,576 B2
Filed 09/29/2004

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for lancet launching device integrated onto a bloodsampling cartridge  
Patent #
US 8,282,577 B2
Filed 06/15/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method of manufacturing a fluid sampling device with improved analyte detecting member configuration  
Patent #
US 8,296,918 B2
Filed 08/23/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,333,710 B2
Filed 10/05/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,337,421 B2
Filed 12/16/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,337,419 B2
Filed 10/04/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,337,420 B2
Filed 03/24/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,343,075 B2
Filed 12/23/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,360,991 B2
Filed 12/23/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,360,992 B2
Filed 11/25/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,366,637 B2
Filed 12/03/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for body fluid sampling and analyte sensing  
Patent #
US 8,372,016 B2
Filed 09/30/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,382,682 B2
Filed 02/06/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,382,683 B2
Filed 03/07/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for multiuse body fluid sampling device with sterility barrier release  
Patent #
US 8,388,551 B2
Filed 05/27/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,403,864 B2
Filed 05/01/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 8,414,503 B2
Filed 03/16/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a multiuse body fluid sampling device with sterility barrier release  
Patent #
US 8,430,828 B2
Filed 01/26/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,435,190 B2
Filed 01/19/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Apparatus and method for penetration with shaft having a sensor for sensing penetration depth  
Patent #
US 8,439,872 B2
Filed 04/26/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Medical data transmission system  
Patent #
US 8,477,026 B2
Filed 09/09/2009

Current Assignee
Roche Diabetes Care Inc.

Sponsoring Entity
Roche Diagnostics Operations Incorporated

Methods and apparatus for lancet actuation  
Patent #
US 8,491,500 B2
Filed 04/16/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 8,496,601 B2
Filed 04/16/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,556,829 B2
Filed 01/27/2009

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,562,545 B2
Filed 12/16/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a multiuse body fluid sampling device with analyte sensing  
Patent #
US 8,574,168 B2
Filed 03/26/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus using optical techniques to measure analyte levels  
Patent #
US 8,574,895 B2
Filed 12/30/2003

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,579,831 B2
Filed 10/06/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,622,930 B2
Filed 07/18/2011

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,202,231 B2
Filed 04/23/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,636,673 B2
Filed 12/01/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Sampling module device and method  
Patent #
US 8,641,643 B2
Filed 04/27/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means  
Patent #
US 8,641,644 B2
Filed 04/23/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for improving fluidic flow and sample capture  
Patent #
US 8,668,656 B2
Filed 12/31/2004

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,679,033 B2
Filed 06/16/2011

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,690,796 B2
Filed 09/29/2006

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for analyte measurement test time  
Patent #
US 8,652,831 B2
Filed 03/26/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Analyte measurement device with a single shot actuator  
Patent #
US 8,702,624 B2
Filed 01/29/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Electric lancet actuator  
Patent #
US 8,721,671 B2
Filed 07/06/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Information provision system, information provision method, program, and server device  
Patent #
US 8,769,002 B2
Filed 04/09/2010

Current Assignee
ARKRAY Inc

Sponsoring Entity
ARKRAY Inc

Body fluid sampling device with a capacitive sensor  
Patent #
US 8,784,335 B2
Filed 07/25/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for penetrating tissue  
Patent #
US 8,808,201 B2
Filed 01/15/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Printable hydrogels for biosensors  
Patent #
US 8,828,203 B2
Filed 05/20/2005

Current Assignee
Sanofi S.A.

Sponsoring Entity
Sanofi S.A.

Methods and systems for processing glucose data measured from a person having diabetes  
Patent #
US 8,843,321 B2
Filed 01/26/2010

Current Assignee
Roche Diabetes Care Inc.

Sponsoring Entity
Roche Diabetes Care Inc.

Method for penetrating tissue  
Patent #
US 8,845,549 B2
Filed 12/02/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,845,550 B2
Filed 12/03/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 8,905,945 B2
Filed 03/29/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for an improved sample capture device  
Patent #
US 8,945,910 B2
Filed 06/19/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 8,965,476 B2
Filed 04/18/2011

Current Assignee
Pelikan Technologies Inc.

Sponsoring Entity
Pelikan Technologies Inc.

Method and apparatus using optical techniques to measure analyte levels  
Patent #
US 9,034,639 B2
Filed 06/26/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,072,842 B2
Filed 07/31/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Analyte measurement device with a single shot actuator  
Patent #
US 9,089,294 B2
Filed 01/16/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,089,678 B2
Filed 05/21/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Low pain penetrating member  
Patent #
US 9,144,401 B2
Filed 12/12/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,186,468 B2
Filed 01/14/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Body fluid sampling module with a continuous compression tissue interface surface  
Patent #
US 9,226,699 B2
Filed 11/09/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 9,248,267 B2
Filed 07/18/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Printable hydrogel for biosensors  
Patent #
US 9,261,476 B2
Filed 04/01/2014

Current Assignee
SanofiAventis SA

Sponsoring Entity
SanofiAventis SA

Analytetesting device  
Patent #
US 9,305,138 B2
Filed 06/05/2015

Current Assignee
Ascensia Diabetes Care Holdings AG

Sponsoring Entity
Ascensia Diabetes Care Holdings AG

Tissue penetration device  
Patent #
US 9,314,194 B2
Filed 01/11/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 9,339,612 B2
Filed 12/16/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a variable user interface  
Patent #
US 9,351,680 B2
Filed 10/14/2004

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Cam drive for managing disposable penetrating member actions with a single motor and motor and control system  
Patent #
US 9,375,169 B2
Filed 01/29/2010

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for analyte detecting device  
Patent #
US 9,386,944 B2
Filed 04/10/2009

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 9,427,532 B2
Filed 09/29/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method for penetrating tissue  
Patent #
US 9,498,160 B2
Filed 09/29/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means  
Patent #
US 9,560,993 B2
Filed 12/20/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for improving fluidic flow and sample capture  
Patent #
US 9,561,000 B2
Filed 12/10/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Sampling module device and method  
Patent #
US 9,694,144 B2
Filed 12/03/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,724,021 B2
Filed 12/08/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a fluid sampling device  
Patent #
US 9,775,553 B2
Filed 10/01/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,795,334 B2
Filed 07/09/2007

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Methods and apparatus for lancet actuation  
Patent #
US 9,795,747 B2
Filed 06/02/2011

Current Assignee
Pelikan Technologies Inc.

Sponsoring Entity
Pelikan Technologies Inc.

Methods and apparatus for lancet actuation  
Patent #
US 9,802,007 B2
Filed 11/18/2013

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for a fluid sampling device  
Patent #
US 9,820,684 B2
Filed 06/03/2005

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Body fluid sampling device with capacitive sensor  
Patent #
US 9,839,386 B2
Filed 06/12/2014

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and apparatus for penetrating tissue  
Patent #
US 9,907,502 B2
Filed 12/16/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Tissue penetration device  
Patent #
US 9,937,298 B2
Filed 12/16/2008

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Low pain penetrating member  
Patent #
US 10,034,628 B2
Filed 12/20/2012

Current Assignee
SanofiAventis Deutschland GmbH

Sponsoring Entity
SanofiAventis Deutschland GmbH

Method and device for predicting physiological values  
Patent #
US 6,546,269 B1
Filed 01/05/2001

Current Assignee
LifeScan IP Holdings LLC

Sponsoring Entity
Cygnus Inc.

Methods and devices for prediction of hypoglycemic events  
Patent #
US 20020106709A1
Filed 08/10/2001

Current Assignee
LifeScan IP Holdings LLC

Sponsoring Entity
LifeScan IP Holdings LLC

Method and arrangement for the neural modelling of a dynamic system with nonlinear stochastic behavior  
Patent #
US 6,272,480 B1
Filed 10/19/1998

Current Assignee
Siemens AG

Sponsoring Entity
Siemens AG

System and method for predicting blood glucose level  
Patent #
US 5,971,922 A
Filed 10/16/1998

Current Assignee
RESEARCH INSTITUTE OF APPLICATION TECHNOLOGIES FOR CHAOS COMPLEX SYSTEMS CO. LTD.

Sponsoring Entity
Kabushiki Kaisha Meidensha

Method and apparatus for executing shortterm prediction of timeseries data  
Patent #
US 5,748,851 A
Filed 02/28/1995

Current Assignee
Kabushiki Kaisha Meidensha

Sponsoring Entity
Kabushiki Kaisha Meidensha

Method for monitoring the condition of a patient  
Patent #
US 5,482,035 A
Filed 03/17/1994

Current Assignee
Instrumentarium Dental Incorporated

Sponsoring Entity
Instrumentarium Dental Incorporated

Analytical system for monitoring a substance to be analyzed in patientblood  
Patent #
US 5,507,288 A
Filed 05/03/1995

Current Assignee
Boehringer Mannheim GmbH

Sponsoring Entity
Boehringer Mannheim GmbH

15 Claims
 1. A method for continuous monitoring of an analyte concentration in the living body of a human or animal, the method comprising:
 determining an analyte values y(t_{n}) correlating with the concentration of the analyte for consecutive points in time t_{n};
calculating a prediction value y(t_{n0}+Δt) over a prediction period Δt based on the analyte value y(t_{n}) using the following equation;
y(t_{n0}+Δt)=F(t_{n0}, t_{n0−Δn}, . . . , t_{(n0−(m−2)Δn)}, t_{(n0−(m−1)Δn)}); and
generating a warning signal if the prediction value y(t_{n0}+Δt) deviates from a predetermined value by more than a threshold value, wherein function F(t_{k}, t_{k−Δn}, t_{k−2Δn}, . . . , t_{k−(m−2)Δn}, t_{k−(m−1)Δn}) depends on the analyte values y(t_{k}), y(t_{k−Δn}), y(t_{k−2Δn}), . . . , y(t_{k−(m−2)Δn}), y(t_{k−(m−1)Δn}) and the function F is used to approximate the progression of the analyte values y(t_{n}) at time t_{n0 }in vicinity U of an analyte value y(t_{n0}) with a predetermined accuracy σ, such that$\begin{array}{c}{\sigma}^{2}\ge \sum _{{t}_{k}\in U}[y\left({t}_{k}\right)F({t}_{k}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{k\Delta \phantom{\rule{0.3em}{0.3ex}}n}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{k2\Delta \phantom{\rule{0.3em}{0.3ex}}n}\hspace{1em}\hspace{1em}\\ {\hspace{1em}\hspace{1em}\Delta \phantom{\rule{0.3em}{0.3ex}}t,\dots \phantom{\rule{0.8em}{0.8ex}}{t}_{\left(k\left(m2\right)\Delta \phantom{\rule{0.3em}{0.3ex}}n\right)}\Delta \phantom{\rule{0.3em}{0.3ex}}t,{t}_{\left(k\left(m1\right)\Delta \phantom{\rule{0.3em}{0.3ex}}n\right)}\Delta \phantom{\rule{0.3em}{0.3ex}}t)]}^{2}\end{array}$ whereby n_{0}, m, and Δn are integers.  View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
 determining an analyte values y(t_{n}) correlating with the concentration of the analyte for consecutive points in time t_{n};
 15. A method for continuous monitoring of an analyte concentration in the living body of a human or animal, the method comprising:
 determining an analyte values y(t_{n}) correlating with the concentration of the analyte for consecutive points in time t_{n};
calculating a prediction value y(t_{n0}+Δt) over a prediction period Δt based on the analyte value y(t_{n}) using the following equation;
y(t_{n0}+Δt)=F(t_{n0}, t_{n0−Δn}, . . . , t_{(n0−(m−2)Δn)}, t_{(n0−(m−1)Δn)}) generating a warning signal if the prediction value y(t_{n0}+Δt) deviates from a predetermined value by more than a threshold value, wherein function F(t_{k}, t_{k−Δn}, t_{k−2Δn}, . . . t_{k−(m−2)Δn}, t_{k−(m−1)Δn}) depends on the analyte values y(t_{k}), y(t_{k−Δn}), y(t_{k−2Δn}), . . . , y(t_{k−(m−2Δn}), y(t_{k−(m−1)Δn}); and
adapting the function F(t_{k}, t_{k−Δn}, t_{k−2Δn}, . . . , t_{k−(m−2)Δn}, t_{k−(m−1)Δn}) in a vicinity U of an analyte value y(t_{n0}+Δt) at a point in time t_{n}=t_{n0}+Δt for a calculated prediction value y(t_{n0}+Δt), such that the adapted function F approximates the progression of analyte values y(t_{n}) in the vicinity U with a predetermined accuracy and an additional prediction value y(t_{n0}+2Δt) is calculated therefrom, whereby n_{0}, m, and Δn are integers.
 determining an analyte values y(t_{n}) correlating with the concentration of the analyte for consecutive points in time t_{n};
1 Specification
The present application claims priority to German Patent Application No. 10 2004 020 160.9, filed Apr. 24, 2004, which is hereby incorporated by reference in its entirety.
TECHNICAL FIELDThe present invention generally relates to a method and a device for monitoring an analyte concentration in the living body of a human or animal. In particular to a method and device for determining analyte values y(t<sub>n</sub>) and using the analyte value in predicting a value for the analyte over a period of time.
BACKGROUNDStudy results have demonstrated that extremely serious longterm corollaries of diabetes mellitus (for example blinding of the patient due to retinopathy) can be prevented by continuous in vivo monitoring of the time profile of the glucose concentration. This allows the dosage of the medication required (insulin) to be adjusted exactly at any point in time and thus the blood sugar levels to be kept within narrow limits at all times like in a healthy person. A method of this type and a suitable device are described in U.S. Pat. No. 5,507,288, for example. The patent describes in particular the continuous monitoring of the glucose concentration in the body of a patient, which is of crucial medical significance.
In order for the medication process to be as efficient as possible it is desired to be able to determine not only a current value of the concentration of an analyte, but also predict future concentration values. The prediction of future values of the concentration of an analyte is of particular significance in the case of diabetes, not only to counteract an increase of the blood glucose concentration beyond a critical value by administering insulin, but also to alert the patient to a decrease of the blood glucose concentration.
The prediction of a future concentration of an analyte value in the living body of a human or animal is made significantly more complicated by the fact that concentration values depend not only on historic values, but also on other parameters, such as food and medication intake or physical exercise.
A method for monitoring the blood glucose concentration is known from U.S. Pat. No. 6,272,480 B1, in which an artificial neuronal network is used to derive a prediction of future blood glucose values from a time series of glucose concentrations that were measured. However, a significant disadvantage of artificial neuronal networks is that they need to be trained prior to their use and yield unreliable results when confronted with time series data outside of their training range.
From EP 1102194 A2, a method is known in which blood glucose concentration values measured at consecutive points in time are extrapolated taking into consideration patientspecific data, such as, in particular, any carbohydrate intake and insulin administration. For practical applications, the need to account for such patientspecific data is a major disadvantage, since accounting for such data is difficult and often errorprone.
SUMMARYIt is against the above background that the present invention proves certain unobvious advantages and advancements over the prior art.
The present invention provides means for continuous monitoring of the concentration of an analyte in the living body of a human or animal and predicting future concentration values. In particular, in this method aside from data of historic concentration values, would not require any patientspecific data, such as food or insulin intake, for the prediction of future concentration values.
A method for continuous monitoring of an analyte concentration by determining its progression in the living body of a human or animal, in which analyte values y(t<sub>n</sub>) correlating with the concentration to be determined are determined for consecutive points in time t<sub>n</sub>. The analyte values are then used for predicting a prediction value for an analyte value y(t<sub>n0</sub>+Δt) over a prediction period Δt.
The method according to the invention can be applied in several steps in order to determine from a prediction value y(t<sub>n0</sub>+Δt) another prediction value y(t<sub>0</sub>+2Δt) even further in the future. A prediction value y(t<sub>0</sub>+nΔt) can thus be determined by multiple application of the method.
These and other features and advantages of the present invention will be more fully understood from the following detailed description of the invention taken together with the accompanying claims. It is noted that the scope of the claims is definitely by the recitations therein and not by the specific discussion of the features and advantages set forth in the present description.
BRIEF DESCRIPTION OF THE DRAWINGSThe invention and preferred embodiments are illustrated in more detail in the following with reference to the figures. The features illustrated and described in the following can be used individually or in combination in order to create preferred further refinements of the invention. In the figures:
FIG. 1 shows a block diagram of a device according to the invention;
FIG. 2 shows a schematic sketch of a sensor suited for the invention;
FIG. 3 shows a measuring signal of a sensor according to FIG. 2;
FIG. 4 shows measured blood glucose concentration values and blood glucose concentration values predicted for a period of 30 minutes; and
FIG. 5 shows a schematic example of a phase space with data points.
Skilled artisans appreciate that elements in the figures are illustrated for simplicity and clarity and have not necessarily been drawn to scale. For example, the dimensions of some of the elements in the figure may be exaggerated relative to other elements to help improve understanding of the embodiment(s) of the present invention.
DETAILED DESCRIPTIONThe following description of the preferred embodiment is merely exemplary in nature and is in no way intended to limit the invention or its application or uses.
The essential components of a device according to the invention are shown in FIG. 1. A sensor 1 measures values at consecutive points in time t<sub>n</sub>. The resulting measurement signal is then transmitted—wireless in the case shown—to a receiver 2 which in turn transmits the measurement signal to an analytical unit 3 containing a microprocessor 4 and a data storage unit 5. Alternatively, both data and commands can be transmitted to the analytical unit 3 by an input unit 6. The results are output by an output unit 7 which may include a display and other common output means. It is selfevident that data processing in the analytical unit 3 is performed in a digital fashion, and corresponding transformers for transforming analogous signals into digital signals are provided. More detailed explanations are not required in this context, since the basic design of devices of this type is known (from U.S. Pat. No. 5,507,288, for example) and the invention is suitable for a broad range of measuring techniques, in which—as described above—different measuring signals that are correlated with the desired working signal are measured.
FIG. 2 shows in the form of a schematic sketch a sensor 1, in which an implantable catheter 10 is used to aspirate interstitial fluid from the subcutaneous fatty tissue by means of a pump 11 and to aspirate the fluid through a photometric measuring unit 12 into a disposal container 13. Inside the photometric measuring unit 12, the tubing 14, through which the fluid is being transported, contains a transparent measuring cell 15, into which primary light emitted by a light sensor 16 is guided. The secondary light resulting from passage of the measuring cell 15 is then measured by means of a photodetector 17 and the resulting signal processed by means of measuring electronics (not shown) to generate a raw signal, which—as is shown in FIG. 1 in an exemplary fashion—is transmitted to an analytical unit 3. The analytical unit 3 is used to determine from the raw signal analyte values y(t<sub>n</sub>) that are correlated with the concentration to be determined for consecutive points in time t<sub>n</sub>. In the scope of the exemplary embodiment, these analyte values y(t<sub>n</sub>) represent the blood glucose level of a subject at a time t<sub>n</sub>.
It is selfevident that the analyte values y(t<sub>n</sub>) can also be determined by other methods, for example methods based on an enzymatic conversion of glucose and subsequent electrochemical detection of the hydrogen peroxide formed in the process.
FIG. 3 shows a curve representing the progression of the blood glucose level of a subject. The two crosses drawn in FIG. 3 denote, in an exemplary fashion, one prediction value each that was determined for a prediction period of 30 minutes by the method to be described in the following. As shown by the good agreement of the left cross and the curve represented as a continuous line, the accuracy of the predicted values is good. It is selfevident that this applies only if the blood glucose level is not affected by an administration of insulin or uptake of carbohydrates during the prediction interval. The right cross in FIG. 3 shows a prediction value that is below a critical threshold value. In the case of a prediction value being this low, a warning signal is generated in order to alert a patient to a dangerous decrease in the blood glucose level such that the decrease can be counteracted by ingestion of carbohydrates.
The analyte values y(t<sub>n</sub>) shown in FIG. 3 in the form of a curve were determined from measured values that were recorded at intervals of 1 second each. To use a measuring rate this high is advantageous in that sufficient data is available for statistical processing of the measured values, but it is not obligatory. For many applications, it is sufficient to determine measured values at intervals of a few minutes e.g. every 2 to 5 minutes.
In the embodiment shown, the measured values were processed by means of a filter algorithm that includes an operation, in which the influence of a current measured value on the working signal is weighted by means of a weighting factor (“controllable filter algorithm”), whereby a signal variation parameter (related in each case to the current point in time, i.e. changing over time) is determined on the basis of signal variations detected in a close temporal relationship to the measurement of the current measured value, and the weighting factor is adapted dynamically as a function of the signal variation parameter determined for the current measured value for the point in time. Filter algorithms of this type are known as Kalmann filter algorithms and have been described, for example, in DE 10343863.7, the content of which is made a content of the present application by way of reference.
For the purposes of the method described in the following, extensive statistical processing of the measured values is not obligatory. Alternatively, it is also feasible, for example, to average over several measured values to obtain an analyte value (t<sub>n</sub>) or to obtain exactly one analyte value y(t<sub>n</sub>) from each measured value.
The analyte values y(t<sub>n</sub>) determined by the analytical unit 12 are then used for predicting a prediction value for an analyte value y(t<sub>n0</sub>+Δt) over a prediction period Δt. The prediction values are predicted by first determining a function, F(t<sub>k</sub>, t<sub>k−Δn</sub>, t<sub>k−2Δn</sub>, . . . , t<sub>k−(m−2)Δn</sub>, t<sub>k−(m−1)Δn</sub>), the function F depends on analyte values y(t<sub>k</sub>), y(t<sub>k−Δn</sub>), y(t<sub>k−2Δn</sub>), . . . , y(t<sub>k−(m−2)Δn</sub>), y(t<sub>k−(m−1)Δn</sub>). The function F which can be used to approximate the progression of the analyte values y(t<sub>n</sub>) at time t<sub>n0 </sub>in a vicinity U of an analyte value y(t<sub>n0</sub>) with a predetermined accuracy σ, such that
<maths id="MATHUS00001" num="00001"><math overflow="scroll"><mtable><mtr><mtd><mrow><mrow><msup><mi>σ</mi><mn>2</mn></msup><mo>≥</mo><mrow><munder><mo>∑</mo><mrow><msub><mi>t</mi><mi>k</mi></msub><mo>∈</mo><mi>U</mi></mrow></munder><mo></mo><mrow><msup><mrow><mo>[</mo><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><msub><mi>t</mi><mi>k</mi></msub><mo>)</mo></mrow></mrow><mo></mo><mrow><mi>F</mi><mo></mo><mrow><mo>(</mo><mrow><mrow><msub><mi>t</mi><mi>k</mi></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>,</mo><mrow><msub><mi>t</mi><mrow><mi>k</mi><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>,</mo><mrow><msub><mi>t</mi><mrow><mi>k</mi><mo></mo><mrow><mn>2</mn><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>,</mo><mi>…</mi><mo></mo><mstyle><mspace width="0.8em" height="0.8ex"/></mstyle><mo>,</mo><mstyle><mtext></mtext></mstyle><mo></mo><mrow><msub><mi>t</mi><mrow><mo>(</mo><mrow><mi>k</mi><mo></mo><mrow><mrow><mo>(</mo><mrow><mi>m</mi><mo></mo><mn>2</mn></mrow><mo>)</mo></mrow><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow><mo>)</mo></mrow></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>,</mo><mrow><msub><mi>t</mi><mrow><mo>(</mo><mrow><mi>k</mi><mo></mo><mrow><mrow><mo>(</mo><mrow><mi>m</mi><mo></mo><mn>1</mn></mrow><mo>)</mo></mrow><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow><mo>)</mo></mrow></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow></mrow><mo>)</mo></mrow></mrow></mrow><mo>]</mo></mrow><mn>2</mn></msup><mo>.</mo></mrow></mrow></mrow><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle></mrow></mtd><mtd><mrow><mo>(</mo><mrow><mi>eq</mi><mo>.</mo><mstyle><mspace width="0.8em" height="0.8ex"/></mstyle><mo></mo><mn>1</mn></mrow><mo>)</mo></mrow></mtd></mtr></mtable></math></maths>
Whereby Δn is an integer.
The function F is used by the analytical unit 12 to calculate a prediction value using the following equation:<FORM>y(t<sub>n0</sub>+Δt)=F(t<sub>n0</sub>, t<sub>n0−Δn</sub>, . . . , t<sub>(n0−(m−2)Δn)</sub>, t<sub>(n0−(m−1)Δn)</sub>) (eq. 2).</FORM>
The concentration of an analyte that is present therein is mathematically treated as a deterministic dynamic system with some possible interference by noise. The development of this system over time is then described as a phase trajectory in a phase space whose dimensionality depends on the number of independent variables influencing the concentration of the analyte to be determined. In the case of diabetes, for example, the number of ingested bread units and the quantity of insulin administered are variables of this type, on which future values of the blood glucose concentration depend.
For practical purposes, the number of variables, on which the analyte concentration to be determined depends, is usually unknown and consequently the dimensionality of the phase space, in which the development of the system over time can be described by means of the phase trajectory, is also unknown.
The invention utilizes the fact that there is no need to know the entire phase trajectory of the system in a possibly highdimensional phase space in order to be able to predict an analyte value. For extrapolating a point on the phase trajectory it is only necessary to know the phase trajectory in a vicinity of that point. In particular, there is no need to consider the entire phase space of the system for extrapolation, but rather it is sufficient to study the dynamics in an artificial, reconstructed phase space of significantly lower dimensionality.
It is sufficient if the dimensionality is high enough to account for all dominant degrees of freedom driving the dynamics of the system. Degrees of freedom with a negligible effect on the dynamics of the system can be left unaccounted for such that the dimensionality of the reconstructed phase space can be selected accordingly lower.
Negligible degrees of freedom are found especially for dynamic systems, in which a subsystem is weakly coupled to the remaining system. Considering diabetes as an example, a subsystem, that depends on the administered quantity of insulin, ingested bread units and physical exercise, is weakly coupled to hormonal regulation mechanisms, which also exert an influence on the blood sugar levels.
A time series of analyte values y(t<sub>n</sub>) determined for consecutive points in time t<sub>n </sub>contains in principle all of the information regarding the dynamic behavior of the system. Therefore, from a finite number of analyte values y(t<sub>n</sub>) determined for consecutive points in time t<sub>n</sub>—often as few as approx. 10 analyte values in the vicinity of the point to be extrapolated are sufficient—a local approximation of the phase trajectory in the vicinity of an analyte value y(t<sub>n0</sub>) at point in time t<sub>n0 </sub>can be determined and extrapolated into the future by a prediction period Δt such that a prediction value of an analyte value y(t<sub>n0</sub>+Δt) can be calculated.
It is important that the analyte values used to determine the function F and thus a local approximation of the phase trajectory were not determined for points in time t<sub>n </sub>that are too close to each other. Otherwise there is a risk that an observed progression is based mainly on measuring errors and noise effects and does not reflect the dynamics over time of a concentration change of the analyte.
In order to be able to reduce the influence of inevitable measuring errors to the extent possible by statistical methods it is desired to determine analyte values y(t<sub>n</sub>) for consecutive points in time t<sub>n </sub>that are as close to each other as possible. Therefore, it may be necessary not to use all analyte values y(t<sub>n</sub>) determined for directly consecutive points in time t<sub>n </sub>for determining a local approximation of the phase trajectory, but rather only every second, third or nth such analyte value that has been determined.
For this reason, equation 1 includes a parameter Δn to ensure that the analyte values y(t<sub>n</sub>) that are used to determine the function F were measured for consecutive points in time t<sub>n </sub>that are separated by sufficiently large time intervals.
Whether or not a function F as determined can be used to approximate the time profile of the analyte values y(t<sub>n</sub>) with a predetermined accuracy, can be tested by means of equation 1. In principle, it is necessary to sum up over all points in time t<sub>k </sub>from the vicinity U of the analyte value y(t<sub>n0</sub>) at time t<sub>n0</sub>. However, this does not exclude that individual analyte values y(t<sub>n</sub>) recognized as erroneous, for example by means of applying suitable filters, are ignored. The function F can be a nonlinear function and depend not only on the analyte values, but in addition on their first and second time derivative. The function F approximates the progression of the analyte values in a vicinity U of a point in time t<sub>n0 </sub>at a predetermined accuracy σ<sup>2</sup>. Although the progression of the analyte values y(t<sub>n</sub>) is usually not linear, however, it is preferable for the function F to be a linear function. It has proven to be particularly favorable to represent the function F using coefficients a<sub>0 </sub>to a<sub>m </sub>suffices as follows:
<maths id="MATHUS00002" num="00002"><math overflow="scroll"><mrow><mi>F</mi><mo>=</mo><mrow><msub><mi>a</mi><mn>0</mn></msub><mo>+</mo><mrow><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>m</mi></munderover><mo></mo><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><msub><mi>t</mi><mrow><mo>(</mo><mrow><mi>k</mi><mo></mo><mrow><mrow><mo>(</mo><mrow><mi>m</mi><mo></mo><mi>j</mi></mrow><mo>)</mo></mrow><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow><mo>)</mo></mrow></msub><mo>)</mo></mrow></mrow><mo></mo><msub><mi>a</mi><mi>j</mi></msub></mrow></mrow></mrow></mrow></math></maths>
The value of the parameter, m, of function F(t<sub>k</sub>, t<sub>k−Δn</sub>, t<sub>k−2Δn</sub>, . . . , t<sub>k−(m−2)Δn</sub>, t<sub>k−(m−1)Δn</sub>) (e.g. in a<sub>m </sub>and t<sub>k−(m−1)Δn</sub>) describes the dimensionality of the phase space, in which the dynamical behavior of the system is approximated.
The coefficients, a<sub>0 </sub>to a<sub>m</sub>, can be determined by minimizing the equation for various analyte values y(t<sub>k</sub>) from the vicinity U.
<maths id="MATHUS00003" num="00003"><math overflow="scroll"><mrow><msup><mi>σ</mi><mn>2</mn></msup><mo>≥</mo><mrow><munder><mo>∑</mo><mrow><msub><mi>t</mi><mi>k</mi></msub><mo>∈</mo><mi>U</mi></mrow></munder><mo></mo><msup><mrow><mo>[</mo><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><msub><mi>t</mi><mi>k</mi></msub><mo>)</mo></mrow></mrow><mo></mo><msub><mi>a</mi><mn>0</mn></msub><mo></mo><mrow><munderover><mo>∑</mo><mrow><mi>i</mi><mo>=</mo><mn>1</mn></mrow><mi>m</mi></munderover><mo></mo><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><mrow><msub><mi>t</mi><mrow><mo>(</mo><mrow><mi>k</mi><mo></mo><mrow><mrow><mo>(</mo><mrow><mi>m</mi><mo></mo><mi>i</mi></mrow><mo>)</mo></mrow><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow><mo>)</mo></mrow></msub><mo></mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>)</mo></mrow></mrow><mo></mo><msub><mi>a</mi><mi>i</mi></msub></mrow></mrow></mrow><mo>]</mo></mrow><mn>2</mn></msup></mrow></mrow></math></maths>
The vicinity U must be selected such that it contains a sufficient number of points in time t<sub>n </sub>for the determination of the coefficients, a<sub>0 </sub>to a<sub>m</sub>. If measured values are detected at a high measuring rate and analyte values y(t<sub>n</sub>) are determined for accordingly tightly spaced points in time t<sub>n</sub>, it is advantageous not to include each and every analyte value that was determined in the equation above for the determination of the coefficients a<sub>0 </sub>bis a<sub>m</sub>, but instead, for example, only every second or third analyte value such that Δn is not necessarily equal to 1, but rather can be a different integer. Although, in principle, the sum for all points in time t<sub>k </sub>in the vicinity U of the time t<sub>n0 </sub>should be obtained in the equation stated above, this does not exclude that analyte values y(t<sub>k</sub>) recognized to be outliers, for example by means of suitable filters, are not included in the analysis.
Ideally, the times t<sub>n</sub>, for which the analyte values y(t<sub>n</sub>) are determined, should be at equidistant time intervals from each other. However, analyte values in a living body of a human or animal possess such high autocorrelation when viewed over extended periods of time, that minor deviations from a constant measuring rate affect the accuracy of the prediction values only to a small degree. For example, the concentrations of lactate—under aerobic conditions—or creatinine display high autocorrelation over a period of several hours. Even relatively rapidly varying analytes, such as glucose, show an autocorrelation coefficient in excess of 0.8 over a period of 30 minutes.
The value of the parameter m in the function F(t<sub>k</sub>, t<sub>k−Δn</sub>, t<sub>k−2Δn</sub>, . . . , t<sub>k−(m2)Δn</sub>, t<sub>k−(m−1)Δn</sub>), i.e. the dimensionality of the relevant phase space, cannot be stated generally for all possible cases, in which the concentration of an analyte in the living body of a human or animal must be monitored. This is due mainly to the fact that the concentration of the various analytes of medical interest depend on different numbers of independent variables. In the case of the blood glucose concentration of a diabetes patient, two such variables are known, i.e. the quantity of bread units ingested and the quantity of insulin administered. In general, it can be said that the parameter does not need to be larger than twice the number of independent variables plus 1. Therefore, m=5 in the present exemplary embodiment illustrated by means of FIG. 3.
As has been mentioned above, the value of the parameter m corresponds to the dimensionality of a phase space reconstructed according to the “Takens time delay embedding” method, in which the dynamic behavior of the system can be described. For practical purposes, m usually has at most a value between 3 and 10, preferably between 5 and 8, and can be determined empirically. One option for determining the dimensionality of the phase space and thus the value of this parameter is provided by the method of socalled “false nearest neighbour” analysis as described in a publication by M. B. Kennel et al., Phys. Rev. A 45 3403 (1995). Reference is made to this publication in a supplementing fashion such that the content thereof is incorporated in the present application by way of reference.
Once the coefficients, a<sub>0 </sub>to a<sub>m</sub>, have been determined they can be used to calculate a prediction value
<maths id="MATHUS00004" num="00004"><math overflow="scroll"><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><mrow><msub><mi>t</mi><mi>n0</mi></msub><mo>+</mo><mrow><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>t</mi></mrow></mrow><mo>)</mo></mrow></mrow><mo>=</mo><mrow><msub><mi>a</mi><mn>0</mn></msub><mo>+</mo><mrow><munderover><mo>∑</mo><mrow><mi>j</mi><mo>=</mo><mn>1</mn></mrow><mi>m</mi></munderover><mo></mo><mrow><mrow><mi>y</mi><mo></mo><mrow><mo>(</mo><msub><mi>t</mi><mrow><mo>(</mo><mrow><mi>n0</mi><mo></mo><mrow><mrow><mo>(</mo><mrow><mi>m</mi><mo></mo><mi>j</mi></mrow><mo>)</mo></mrow><mo></mo><mi>Δ</mi><mo></mo><mstyle><mspace width="0.3em" height="0.3ex"/></mstyle><mo></mo><mi>n</mi></mrow></mrow><mo>)</mo></mrow></msub><mo>)</mo></mrow></mrow><mo></mo><msub><mi>a</mi><mi>j</mi></msub></mrow></mrow></mrow></mrow></math></maths>
Subsequently, a prediction value determined accordingly is compared to a predetermined lower and/or upper threshold value and a warning signal is generated if that value is below or above the threshold value, respectively.
When a patient responds to a warning signal of this type by ingesting carbohydrates or administering a dose of insulin, it takes a while before the blood glucose concentration is affected by such ingestion of carbohydrates or administration of insulin. For this reason, it is usually necessary to predict analyte value 10 to 90 minutes, preferably 20 to 40 min, into the future such that there is sufficient time to counteract a dangerous increase or decrease of the analyte concentration. It has been found that analyte values are better predicted over extended periods of time if, rather than selecting an accordingly large prediction period (e.g. Δt=30 min) in a single step, the procedure is applied in multiple smaller steps of 5 minutes, for example. In each additional step coefficients a<sub>0 </sub>to a<sub>m </sub>are determined for an already calculated prediction value y(t<sub>n0</sub>+Δt), which coefficients are used to approximate the progression of analyte values y(t<sub>n</sub>) in a vicinity U of the analyte value at point in time t<sub>n0</sub>+Δt. The results are used to calculate another prediction value y(t<sub>n0</sub>+2Δt). In a stepwise procedure of this type, the prediction period Δt of the individual steps should be selected to be equal to the interval between times t<sub>n</sub>, for which the analyte values y(t<sub>n</sub>) used for calculating the prediction values were determined. If the time interval between consecutive points in time t<sub>n </sub>equals dt, this means that the prediction period is given by Δt=dt·Δn. In the process, it is important that the coefficients, a<sub>0 </sub>to a<sub>m</sub>, used to approximate the progression of the analyte values in the vicinity U are redetermined in each step for a vicinity U that is shifted by the prediction period Δt.
Instead of predicting an analyte value y(t<sub>n</sub>) for a point in time t<sub>n </sub>in the future by means of multiple application of the method in multiple steps, it is also feasible to use a suitably larger prediction period Δt and coefficients, a<sub>0 </sub>to a<sub>m</sub>, determined accordingly to predict in a single step an analyte value y(t<sub>n</sub>+Δt) in the distant future.
The method described above cannot only be used to predict future analyte values, but also to test analyte values y(t<sub>n</sub>) that were determined for the past and identify false analyte values y(t<sub>n</sub>) which are due to outliers or measuring errors. The generally very good agreement between the measured analyte values y(t<sub>n</sub>) and the prediction values is shown in FIG. 4 in an exemplary fashion. The smooth continuous curve represents the time profile of the prediction values, whereas the curve showing strong shortterm variations represents the time profile of the measured values. The prediction period was 2 min, and a total of 15 steps were performed consecutively such that analyte values were predicted for a period of 30 minutes. Therefore, the y axis does not represent the blood glucose concentration in FIG. 4, but rather the intensity of the measuring signal on which the blood glucose determination is based as detected electrochemically (in units of nanoampere).
The finding that the dynamic behavior of a deterministic system can be described by a finite number of analyte values y(t<sub>n</sub>) that are determined for consecutive points in time t<sub>n</sub>, on which the function F depends, is based on the “Takens time delay embedding” method described in the publication by T. Schreiber in Phys. Rep. 85, 1–64 (1999). According to the terminology used in the publication of T. Schreiber, the interval between consecutive points in time, for which analyte values y(t<sub>n</sub>) are determined, is called delay time. Reference is made to the publication of T. Schreiber in a supplementing fashion such that the content thereof is incorporated in the present application by way of reference. For the calculation, it can be advantageous to transform the coordinates y(t<sub>k</sub>), y(t<sub>k−Δn</sub>), y(t<sub>k−2Δn</sub>), . . . , y(t<sub>k−(m−2)Δn</sub>), y(t<sub>k−(m−1)Δn</sub>) and determine F as a function of a set of transformed coordinates Ty(t<sub>k</sub>), Ty(t<sub>k−Δn</sub>), . . . , Ty(t<sub>k−(m−1)Δn</sub>).
It is preferable to perform a linear transformation on the set of coordinates. Hereby, it is useful for the transformed coordinates to be socalled latent coordinates aligned along the main axes of a socalled ellipsoid of variance, as is illustrated in FIG. 5. An ellipsoid of variance of this type is drawn in a twodimensional phase space in FIG. 5, which phase space is represented by its delay coordinates, y(t) and y(tk). The ellipsoid of variance surrounds data points that are indicated by black circles, which, when connected according to their sequence in time, form a phase trajectory.
The ellipsoid of variance can be calculated from the scattering of the data points in the phase space, whereby the main axes of the ellipsoid indicate the variance of the data points in the corresponding direction of the phase space. FIG. 5 also shows the new phase space obtained by transformation along with its coordinates, T(1) and T(2). The first latent coordinate T(1) extends along the largest axis of inertia of the ellipsoid of variance, the second latent coordinate T(2) along the secondtolargest axis of inertia. Numerically, a transformation to latent coordinates can be performed for example by socalled principal component analysis (M. Otto, Chemometrics, Wiley, Weinheim (Germany), 1999, pages 124 to 133) or singular value decomposition (W. H. Press et al., Numerical Recipes, Cambridge University Press, Cambridge (UK), 1989, pages 52 to 61).
By performing a transformation to latent coordinates of this type, it is possible to achieve that one or several of the transformed coordinates have a negligible effect on the function F at the predetermined accuracy σ such that only a correspondingly smaller number of transformed coordinates needs to be included in the analysis in the calculation of function F.
These and other features and advantages of the present invention should be more fully understood from the above detailed description of the invention taken together with the accompanying claims. It is noted that the scope of the claims is defined by the recitations therein and not by the specific discussion of the features and advantages set forth in the present description.
It is noted that terms like “preferably”, “commonly” and “typically” are not utilized therein to limit the scope of the claimed invention or to imply that certain features are critical, essential or even important to applications of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the present invention.
It is noted that terms like “preferably”, “commonly”, and “typically” are not utilized herein to limit the scope of the claimed invention or to imply that certain features are critical, essential, or even important to the structure or function of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the present invention.
For the purposes of describing and defining the present invention it is noted that the term “substantially” is utilized herein to represent the inherent degree of uncertainty that may be attributed to any quantitative comparison, value, measurement, or other representation. The term “substantially” is also utilized herein to represent the degree by which a quantitative representation may very from a stated reference without resulting in a change in the basic function of the subject matter at issue.
Having described the invention in detail and by reference to specific embodiments thereof, it will be apparent that modification and variations are possible without departing from the scope of the invention defined in the appended claims. More specifically, although some aspects of the present invention are identified herein as preferred or particularly advantageous, it is contemplated that the present invention is not necessarily limed to these preferred aspects of the invention.